UY25048A1 - Composiciones para el tratamiento de la diabetes mellitus - Google Patents

Composiciones para el tratamiento de la diabetes mellitus

Info

Publication number
UY25048A1
UY25048A1 UY25048A UY25048A UY25048A1 UY 25048 A1 UY25048 A1 UY 25048A1 UY 25048 A UY25048 A UY 25048A UY 25048 A UY25048 A UY 25048A UY 25048 A1 UY25048 A1 UY 25048A1
Authority
UY
Uruguay
Prior art keywords
diabetes mellitus
treatment
compositions
mammal
present
Prior art date
Application number
UY25048A
Other languages
English (en)
Inventor
Stephen Alistair Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26311744&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY25048(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9712854.0A external-priority patent/GB9712854D0/en
Priority claimed from GBGB9806710.1A external-priority patent/GB9806710D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of UY25048A1 publication Critical patent/UY25048A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona una combinación que comprende de 2 a 8 mg de 5-(4-(2-(N-metil-N-(2-piridil)amino)etoxi)bencil)tiazolidina-2,4-diona, compuesto (I), o una forma tautomérica del mismo y/o un derivado farmacéuticamente aceptable del mismo, y un secretagogo de insulina el cual es glibencalmida, glipizida, gliclazida, glimepirida, tolazamida o tolbutamina. La presente invención se refiere a un método para el tratamiento de diabetes mellitus y procesos asociados a la diabetes mellitus en un mamífero, cuyo método comprende administrar una cantidad eficaz, no tóxica y farmacéuticamente eficaz de un sensibilizador a la insulina y un secretagogo de insulina a un mamífero con necesidad de ello.
UY25048A 1997-06-18 1998-06-18 Composiciones para el tratamiento de la diabetes mellitus UY25048A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9712854.0A GB9712854D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
GBGB9806710.1A GB9806710D0 (en) 1998-03-27 1998-03-27 Novel method

Publications (1)

Publication Number Publication Date
UY25048A1 true UY25048A1 (es) 2000-09-29

Family

ID=26311744

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25048A UY25048A1 (es) 1997-06-18 1998-06-18 Composiciones para el tratamiento de la diabetes mellitus

Country Status (34)

Country Link
EP (3) EP1671637A3 (es)
JP (1) JP2001523270A (es)
KR (3) KR20010013840A (es)
CN (1) CN1168451C (es)
AP (1) AP1600A (es)
AR (2) AR008025A1 (es)
AT (1) ATE353654T1 (es)
AU (1) AU8539298A (es)
BG (2) BG64817B1 (es)
BR (1) BR9810142A (es)
CA (1) CA2294385C (es)
CO (1) CO4940457A1 (es)
CZ (1) CZ299310B6 (es)
DE (1) DE69837089T2 (es)
DZ (1) DZ2522A1 (es)
EA (1) EA003025B1 (es)
ES (1) ES2283064T3 (es)
HK (1) HK1028200A1 (es)
ID (1) ID24065A (es)
IL (1) IL133137A (es)
IN (1) IN189319B (es)
MA (1) MA24571A1 (es)
MY (1) MY125855A (es)
NO (3) NO326263B1 (es)
NZ (1) NZ501163A (es)
OA (1) OA11510A (es)
PE (1) PE108199A1 (es)
PL (2) PL198018B1 (es)
SK (1) SK286028B6 (es)
TR (1) TR199903096T2 (es)
TW (1) TW542717B (es)
UA (1) UA67743C2 (es)
UY (1) UY25048A1 (es)
WO (1) WO1998057649A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9715295D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
BR0009934A (pt) 1999-04-23 2002-06-04 Smithkline Beecham Plc Produto farmacêutico
CA2389237A1 (en) 1999-11-01 2001-05-10 Wisconsin Alumni Research Foundation Abc1 modulation for the modulation of cholesterol transport
EP1349531A1 (en) 2001-01-12 2003-10-08 Sun Pharmaceuticals Industries Ltd. Spaced drug delivery system
KR100698595B1 (ko) * 2003-09-29 2007-03-21 보령제약 주식회사 무정형 또는 준결정형 글리메피리드, 이의 제조방법 및 무정형 또는 준결정형 글리메피리드를 포함하는 약학적조성물
HUE028576T2 (en) * 2003-10-31 2016-12-28 Takeda Pharmaceuticals Co Solid preparation containing pioglitazone, glimepiride and polyoxyethylene sorbitan fatty acid ester
TWI384985B (zh) 2005-12-22 2013-02-11 Takeda Pharmaceutical 固體製劑
CN104158867B (zh) * 2014-08-06 2017-05-17 电子科技大学 一种基于wave协议的信息多跳转发方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4582839A (en) 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
DK173350B1 (da) 1985-02-26 2000-08-07 Sankyo Co Thiazolidinderivater, deres fremstilling og farmaceutisk paæparat indeholdende dem
JPH06779B2 (ja) 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
ES2137915T3 (es) * 1987-09-04 2000-01-01 Beecham Group Plc Derivados de tiazolidindiona sustituida.
US4791125A (en) 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
US5061717A (en) 1988-03-08 1991-10-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
MX15171A (es) 1988-03-08 1993-05-01 Pfizer Derivados de tiazolidinodiona hipoglicemicos
WO1991007107A1 (en) 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
PL296945A1 (es) 1990-07-03 1992-07-13 Yamanouchi Pharma Co Ltd
KR930701420A (ko) 1990-08-23 1993-06-11 알렌 제이. 스피겔 혈당저하제로서의 하이드록시우레아 유도체
JPH04210683A (ja) 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
SK109993A3 (en) 1991-04-11 1994-12-07 Upjohn Co Thiazolidinedione derivatives producing and use thereof
US5183823A (en) 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
TW222626B (es) 1991-07-22 1994-04-21 Pfizer
FR2680512B1 (fr) 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
DK0601001T3 (da) * 1991-08-26 1997-10-20 Upjohn Co Flydende næringsmiddelprodukt indeholdende 3-guanidinopropionsyre.
JPH05271204A (ja) 1992-03-26 1993-10-19 Japan Tobacco Inc 新規なトリアジン誘導体
US5264451A (en) 1992-04-07 1993-11-23 American Home Products Corporation Process for treating hyperglycemia using trifluoromethyl substituted 3H-pyrazol-3-ones
JPH07505647A (ja) 1992-04-10 1995-06-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 複素環化合物および２型糖尿病の治療におけるそれらの使用
AU4104593A (en) 1992-05-05 1993-11-29 Upjohn Company, The A process for producing pioglitazone metabolite
CA2139442A1 (en) 1992-07-03 1994-01-20 David Haigh Heterocyclic compounds as pharmaceutical
US5232945A (en) 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5457109A (en) 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes

Also Published As

Publication number Publication date
UA67743C2 (uk) 2004-07-15
BG64817B1 (bg) 2006-05-31
AP9901717A0 (en) 1999-12-31
EP1671637A3 (en) 2007-12-19
CA2294385C (en) 2007-06-05
SK179199A3 (en) 2000-11-07
NO996264D0 (no) 1999-12-17
KR20080011356A (ko) 2008-02-01
IL133137A (en) 2004-02-08
NO996264L (no) 2000-02-17
TW542717B (en) 2003-07-21
PL337510A1 (en) 2000-08-28
DE69837089D1 (de) 2007-03-29
HK1028200A1 (en) 2001-02-09
ES2283064T3 (es) 2007-10-16
EP0999845B1 (en) 2007-02-14
CZ299310B6 (cs) 2008-06-18
MY125855A (en) 2006-08-30
OA11510A (en) 2004-02-03
DE69837089T2 (de) 2007-06-21
IN189319B (es) 2003-02-08
DZ2522A1 (fr) 2003-02-01
TR199903096T2 (xx) 2000-08-21
EP2266576A1 (en) 2010-12-29
SK286028B6 (sk) 2008-01-07
BR9810142A (pt) 2000-08-08
CO4940457A1 (es) 2000-07-24
IL133137A0 (en) 2001-03-19
JP2001523270A (ja) 2001-11-20
AR008025A1 (es) 1999-12-09
BG104058A (en) 2000-10-31
NO2009002I1 (no) 2009-03-02
EA200000039A1 (ru) 2000-08-28
AP1600A (en) 2006-04-28
CZ9904577A3 (en) 2001-05-16
KR20010013840A (ko) 2001-02-26
EP0999845A1 (en) 2000-05-17
BG109397A (bg) 2006-05-31
ID24065A (id) 2000-07-06
AU8539298A (en) 1999-01-04
PL198018B1 (pl) 2008-05-30
EP1671637A2 (en) 2006-06-21
EA003025B1 (ru) 2002-12-26
MA24571A1 (fr) 1998-12-31
ATE353654T1 (de) 2007-03-15
NO326263B1 (no) 2008-10-27
KR20070011651A (ko) 2007-01-24
NZ501163A (en) 2002-02-01
AR012996A1 (es) 2000-11-22
CN1168451C (zh) 2004-09-29
PE108199A1 (es) 2000-01-14
CA2294385A1 (en) 1998-12-23
NO20083276L (no) 2000-02-17
WO1998057649A1 (en) 1998-12-23
CN1260719A (zh) 2000-07-19

Similar Documents

Publication Publication Date Title
UY25049A1 (es) Composiciones para tratamiento para diabetes mellitus
EA200601145A1 (ru) Таблетка замедленного высвобождения сенсибилизатора к инсулину и других антидиабетических агентов
AR057970A2 (es) Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus y procedimientos para preprar dichas composiciones
KR940006590A (ko) 알쯔하이머 질환 치료용 및 혈당저하제로서 유용한 화합물
CY1105254T1 (el) Θepαπεια του διαβητη με θειαζολιδινδιονη, εκκριταγωγο ινσουλινης και διγουανιδιο
EP1593379A3 (en) Uses of PPAR-gamma agonists in neutrophil-induced diseases
KR930702287A (ko) 신규화합물
UY25048A1 (es) Composiciones para el tratamiento de la diabetes mellitus
UY25050A1 (es) Metodo de tratamiento para diabetes mellitus
EA200601144A1 (ru) Таблетка замедленного высвобождения сенсибилизатора к инсулину
AR008198A1 (es) Procedimiento para preparar una composicion farmaceutica de 5-[4-[2-(n- metil-n-(2-piridil)amino)etoxi]bencil]tiazolin-2,4-diona
NZ515555A (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
UY25051A1 (es) Composiciones para el tratamiento de diabetes mellitus
PE99499A1 (es) Composicion farmaceutica para el tratamiento de la diabetes
UY26112A1 (es) Dihidrato de hidrocloruro de 5- [4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidina-2,4-diona
AP1715A (en) The hydrochloride salt of 5-[ 4 -[2 -(n-methyl-n- (2-pyridyl) amino) ethoxy]benzyl]thiazolidine -2,4-dione
HK1057751A1 (en) A thiazolidinedione derivative and its use as antidiabetic
PE20001239A1 (es) Composicion de un sensibilizador de insulina
AP1841A (en) A thiazolidinedione derivative and its use as antidiabetic.
MXPA02012100A (es) Sal de tiazodilindiona para el tratamiento de la diabetes mellitus.
NZ524933A (en) Sodium salts of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione and pharmaceutical composition thereof
EA200300232A1 (ru) Тартратные соли производного тиазолидиндиона
TH36758A (th) กรรมวิธีในการรักษาโรคเบาหวานด้วยไธอะโซลิดีนไดโอนและเมทฟอร์มิน
TH21154B (th) กรรมวิธีในการรักษาโรคเบาหวานด้วยไธอะโซลิดีนไดโอนและเมทฟอร์มิน
CO5150180A1 (es) Nueva composicion y uso liberacion modificada

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20101118